Please login to the form below

Not currently logged in
Email:
Password:

Ex-BMS exec jumps to Gilead to lead research group

Gilead appoints Michael Quigley to lead research team

A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.

Michael QuigleyMichael Quigley (pictured left) joins Gilead from BMS, where he most recently served as vice president and head of the company’s Tumour Microenvironment Modulation Thematic Research Center and site head of the Redwood City, California location.

At BMS, Quigley held responsibility for setting the strategy for the company’s oncology discovery portfolio and business development activities. He also oversaw target identification, validation and preclinical development of large and small molecule therapies.

Gilead has also simultaneously announced the promotion of Linda Higgins, who has recently taken on the role of senior vice president and head of external innovation.

Linda HigginsHiggins (pictured right) joined Gilead in 2010 to lead an expansion of the company’s biology organisation. That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.

Under her leadership, Gilead’s biology organisation supported the discovery and development of eight marketed products and the development of more than 30 compounds into development.

“We are very pleased to welcome Mike to Gilead and Linda to her new role, as we seek to build and scale our access to scientific innovation, both internally and externally,” commented William Lee. “These appointments strengthen our research discovery organisation and will help position us to reach our ambitious goal of bringing 10 new transformative therapies to patients over the next 10 years.”

Article by
Lucy Parsons

21st February 2020

From: Research

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics